Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEPL-G Regimen in NKTCL-HLH
NCT07525466Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone-liposome, golidocitinib in Extranodal NK/T-cell lymphoma (ENKTL), hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Tongren Hospital. Started Apr 2026; status: recruiting.
02
Drugs
mitoxantrone-liposomegolidocitinib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT07525466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525466.